The Androgen Receptor: Structure, Mutations, and Antiandrogens

References

• Greenlee R.T., Hill-Harmon M.B., Murray T., Thun M. Cancer Statistics, 2001. CA—Cancer J. Clin. 2001; 51(1)15–36
   PubMed Web of Science ®Google Scholar
• Henshall S.M., Quinn D.I., Lee C.S., Head D.R., Golovsky D., Brenner P.C., Delprado W., Stricker P.D., Grygiel J.J., Sutherland R.L. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res. 2001; 61(2)423–427
   PubMed Web of Science ®Google Scholar
• Culig Z., Hobisch A., Bartsch G., Klocker H. Expression and function of androgen receptor in carcinoma of the prostate. Microsc. Res. Tech. 2000; 51(5)447–455
   PubMed Web of Science ®Google Scholar
• Brinkmann A.O., Trapman J. Androgen receptor mutants that affect normal growth and development. Cancer Surv. 1992; 14: 95–111
   PubMedGoogle Scholar
• Evans R.M. The steroid and thyroid hormone receptor superfamily. Science 1988; 240(4854)889–895
   PubMed Web of Science ®Google Scholar
• Janne O.A., Palvimo J.J., Kallio P., Mehto M. Androgen receptor and mechanism of androgen action. Ann. Med. 1993; 25(1)83–89
   PubMed Web of Science ®Google Scholar
• Berger F.G., Watson G. Androgen-regulated gene expression. Annu. Rev. Physiol. 1989; 51: 51–65
   PubMed Web of Science ®Google Scholar
• Huggins C., Hodges C. Studies on prostatic cance: the effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941; 1: 293–297
   Google Scholar
• Muenchen H.J., Lin D.L., Poncza P.J., McLean L.L., Direttee M.L., Keller E.T., Pienta K.J. Re-expression of functional androgen receptor in androgen-independent prostate cancer cells. J. Biol. Chem. 2000; 13: 13
   Google Scholar
• Jenster G. The role of the androgen receptor in the development and progression of prostate cancer. Semin. Oncol. 1999; 26(4)407–421
   PubMed Web of Science ®Google Scholar
• Chang C.S., Kokontis J., Liao S.T. Structural analysis of complementary DNA and amino acid sequences of human and rat androgen receptors. Proc. Natl Acad. Sci. U.S.A. 1988; 85(19)7211–7215
   PubMed Web of Science ®Google Scholar
• Kuiper G.G., Faber P.W., van Rooij H.C., van der Korput J.A., Ris-Stalpers C., Klaassen P., Trapman J., Brinkmann A.O. Structural organization of the human androgen receptor gene. J. Mol. Endocrinol. 1989; 2(3)R1–R4
   PubMed Web of Science ®Google Scholar
• Trapman J., Klaassen P., Kuiper G.G., van der Korput J.A., Faber P.W., van Rooij H.C., Geurts van Kessel A., Voorhorst M.M., Mulder E., Brinkmann A.O. Cloning, structure and expression of a cDNA encoding the human androgen receptor. Biochem. Biophys. Res. Commun. 1988; 153(1)241–248
   PubMed Web of Science ®Google Scholar
• Brinkmann A.O., Trapman J. Genetic analysis of androgen receptors in development and disease. Adv. Pharmacol. 2000; 47: 317–341
   PubMedGoogle Scholar
• Gao T., McPhaul M.J. Functional activities of the A and B forms of the human androgen receptor in response to androgen receptor agonists and antagonists. Mol. Endocrinol. 1998; 12(5)654–663
   PubMed Web of Science ®Google Scholar
• Catalano M.G., Pfeffer U., Raineri M., Ferro P., Curto A., Capuzzi P., Corno F., Berta L., Fortunati N. Altered expression of androgen-receptor isoforms in human colon-cancer tissues. Int. J. Cancer 2000; 86(3)325–330
   PubMed Web of Science ®Google Scholar
• Brinkmann A.O., Jenster G., Kuiper G.G., Ris C., van Laar J.H., van der Korput J.A., Degenhart H.J., Trifiro M.A., Pinsky L., Romalo G., et al. The human androgen receptor: structure/function relationship in normal and pathological situations. J. Steroid. Biochem. Mol. Biol. 1992; 41(3–8)361–368
   PubMed Web of Science ®Google Scholar
• Chang C., Saltzman A., Yeh S., Young W., Keller E., Lee H.J., Wang C., Mizokami A. Androgen receptor: an overview. Crit. Rev. Eukaryot Gene Expr. 1995; 5(2)97–125
   PubMed Web of Science ®Google Scholar
• Lubahn D.B., Joseph D.R., Sar M., Tan J., Higgs H.N., Larson R.E., French F.S., Wilson E.M. The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate. Mol. Endocrinol. 1988; 2(12)1265–1275
   PubMed Web of Science ®Google Scholar
• Giovannucci E., Stampfer M.J., Krithivas K., Brown M., Dahl D., Brufsky A., Talcott J., Hennekens C.H., Kantoff P.W. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc. Natl Acad. Sci. U.S.A. 1997; 94(7)3320–3323
   PubMed Web of Science ®Google Scholar
• Tan J.A., Joseph D.R., Quarmby V.E., Lubahn D.B., Sar M., French F.S., Wilson E.M. The rat androgen receptor: primary structure, autoregulation of its messenger ribonucleic acid, and immunocytochemical localization of the receptor protein. Mol. Endocrinol. 1988; 2(12)1276–1285
   PubMed Web of Science ®Google Scholar
• Coetzee G.A., Ross R.K. Re: prostate cancer and the androgen receptor. J. Natl Cancer Inst. 1994; 86(11)872–873
   PubMed Web of Science ®Google Scholar
• Choong C.S., Wilson E.M. Trinucleotide repeats in the human androgen receptor: a molecular basis for disease. J. Mol. Endocrinol. 1998; 21(3)235–257
   PubMed Web of Science ®Google Scholar
• Bentel J.M., Tilley W.D. Androgen receptor in prostate cancer. J. Endocrinol. 1996; 151(1)1–11
   PubMed Web of Science ®Google Scholar
• Roy A.K., Lavrovsky Y., Song C.S., Chen S., Jung M.H., Velu N.K., Bi B.Y., Chatterjee B. Regulation of androgen action. Vitam. Horm. 1999; 55: 309–352
   PubMed Web of Science ®Google Scholar
• Edwards A., Hammond H.A., Jin L., Caskey C.T., Chakraborty R. Genetic variation at five trimeric and tetrarmeric tandem repeat loci in four human population groups. Genomics 1992; 12(2)241–253
   PubMed Web of Science ®Google Scholar
• Irvine R.A., Yu M.C., Ross R.K., Coetzee G.A. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res. 1995; 55(9)1937–1940
   PubMed Web of Science ®Google Scholar
• Giovannucci E., Platz E.A., Stampfer M.J., Chan A., Krithivas K., Kawachi I., Willett W.C., Kantoff P.W. The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia. Urology 1999; 53(1)121–125
   PubMed Web of Science ®Google Scholar
• Bratt O., Borg A., Kristoffersson U., Lundgren R., Zhang Q.X., Olsson H. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. Br. J. Cancer 1999; 81(4)672–676
   PubMed Web of Science ®Google Scholar
• Ingles S.A., Ross R.K., Yu M.C., Irvine R.A., La Pera G., Haile R.W., Coetzee G.A. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J. Natl Cancer Inst. 1997; 89(2)166–170
   PubMed Web of Science ®Google Scholar
• Hakimi J.M., Schoenberg M.P., Rondinelli R.H., Piantdosi S., Barrack E.R. Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer. Clin. Cancer Res. 1997; 3(9)1599–1608
   PubMed Web of Science ®Google Scholar
• Beilin J., Harewood L., Frydenberg M., Mameghan H., Martyres R.F., Farish S.J., Yue C., Deam D.R., Byron K.A., Zajac J.D. A case-control study of the androgen receptor gene CAG repeat polymorphism in Australian prostate carcinoma subjects. Cancer 2001; 92(4)941–949
   PubMed Web of Science ®Google Scholar
• Sawaya M.E., Shalita A.R. Androgen receptor polymorphisms (CAG repeat lengths) in androgenetic alopecia, hirsutism, and acne. J. Cutan. Med., Surg. 1998; 3(1)9–15
   PubMedGoogle Scholar
• Kawasaki T., Ushiyama T., Ueyama H., Inoue K., Mori K., Ohkubo I., Hukuda S. Polymorphic CAG repeats of the androgen receptor gene and rheumatoid arthritis. Ann. Rheum. Dis. 1999; 58(8)500–502
   PubMed Web of Science ®Google Scholar
• La Spada A.R., Roling D.B., Harding A.E., Warner C.L., Spiegel R., Hausmanowa-Petrusewicz I., Yee W.C., Fischbeck K.H. Meiotic stability and genotype-phenotype correlation of the trinucleotide repeat in X-linked spinal bulbar muscular atrophy. Nat. Genet. 1992; 2(4)301–304
   PubMed Web of Science ®Google Scholar
• Igarashi S., Tanno Y., Onodera O., Yamazaki M., Sato S., Ishikawa A., Miyatani N., Nagashima M., Ishikawa Y., Sahashi K., et al. Strong correlation between the number of CAG repeats in androgen receptor genes and the clinical onset of features of spinal and bulbar muscular atrophy. Neurology 1992; 42(12)2300–2302
   PubMed Web of Science ®Google Scholar
• Rebbeck T.R., Kantoff P.W., Krithivas K., Neuhausen S., Blackwood M.A., Godwin A.K., Daly M.B., Narod S.A., Garber J.E., Lynch H.T., Weber B.L., Brown M. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am. J. Hum. Genet. 1999; 64(5)1371–1377
   PubMed Web of Science ®Google Scholar
• Mitas M. Trinucleotide repeats associated with human disease. Nucleic Acids Res. 1997; 25(12)2245–2254
   PubMed Web of Science ®Google Scholar
• Platz E.A., Giovannucci E., Dahl D.M., Krithivas K., Hennekens C.H., Brown M., Stampfer M.J., Kantoff P.W. The androgen receptor gene GGN microsatellite and prostate cancer risk. Cancer Epidemiol. Biomark. Prev. 1998; 7(5)379–384
   PubMed Web of Science ®Google Scholar
• Stanford J.L., Just J.J., Gibbs M., Wicklund K.G., Neal C.L., Blumenstein B.A., Ostrander E.A. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res. 1997; 57(6)1194–1198
   PubMed Web of Science ®Google Scholar
• Correa-Cerro L., Wohr G., Haussler J., Berthon P., Drelon E., Mangin P., Fournier G., Cussenot O., Kraus P., Just W., Paiss T., Cantu J.M., Vogel W. (CAG)nCAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French–German population. Eur. J. Hum. Genet. 1999; 7(3)357–362
   PubMed Web of Science ®Google Scholar
• Edwards S.M., Badzioch M.D., Minter R., Hamoudi R., Collins N., Ardern-Jones A., Dowe A., Osborne S., Kelly J., Shearer R., Easton D.F., Saunders G.F., Dearnaley D.P., Eeles R.A. Androgen receptor polymorphisms: association with prostate cancer risk, relapse and overall survival. Int. J. Cancer 1999; 84(5)458–465
   PubMed Web of Science ®Google Scholar
• Cude K.J., Dixon S.C., Guo Y., Lisella J., Figg W.D. The androgen receptor: genetic considerations in the development and treatment of prostate cancer. J. Mol. Med. 1999; 77(5)419–426
   PubMed Web of Science ®Google Scholar
• Chamberlain N.L., Driver E.D., Miesfeld R.L. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res. 1994; 22(15)3181–3186
   PubMed Web of Science ®Google Scholar
• Kazemi-Esfarjani P., Trifuro M.A., Pinsky L. Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: possible pathogenetic relevance for the (CAG)n-expanded neuronopathies. Hum. Mol. Genet. 1999; 4(4)523–527
   Google Scholar
• O'Malley B. The steroid receptor superfamily: more excitement predicted for the future. Mol. Endocrinol. 1990; 4(3)363–369
   PubMed Web of Science ®Google Scholar
• Fuller P.J. The steroid receptor superfamily: mechanisms of diversity. FASEB J. 1991; 5(15)3092–3099
   PubMed Web of Science ®Google Scholar
• Wahli W., Martinez E. Superfamily of steroid nuclear receptors: positive and negative regulators of gene expression. FASEB J. 1991; 5(9)2243–2249
   PubMed Web of Science ®Google Scholar
• Freedman L.P. Anatomy of the steroid receptor zinc finger region. Endocr. Rev. 1992; 13(2)129–145
   PubMed Web of Science ®Google Scholar
• Luisi B.F., Xu W.X., Otwinowski Z., Freedman L.P., Yamamoto K.R., Sigler P.B. Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA [see comments]. Nature 1991; 352(6335)497–505
   PubMed Web of Science ®Google Scholar
• Griffin J.E. Androgen resistance—the clinical and molecular spectrum. N. Engl. J. Med. 1992; 326(9)611–618
   PubMed Web of Science ®Google Scholar
• Quigley C.A., Evans B.A., Simental J.A., Marschke K.B., Sar M., Lubahn D.B., Davies P., Hughes I.A., Wilson E.M., French F.S. Complete androgen insensitivity due to deletion of exon C of the androgen receptor gene highlights the functional importance of the second zinc finger of the androgen receptor in vivo. Mol. Endocrinol. 1993; 6(7)1103–1112
   Web of Science ®Google Scholar
• Klocker H., Kaspar F., Eberle J., Uberreiter S., Radmayr C., Bartsch G. Point mutation in the DNA binding domain of the androgen receptor in two families with Reifenstein syndrome. Am. J. Hum. Genet. 1992; 50(6)1318–1327
   PubMed Web of Science ®Google Scholar
• Mowszowicz I., Mestayer C. Mutations of the androgen receptor gene a possible role in prostate cancer. Bull. Cancer 1997; 84(2)183–188
   PubMed Web of Science ®Google Scholar
• Wilson J.D., George F.W., Griffin J.E. The hormonal control of sexual development. Science 1981; 211(4488)1278–1284
   PubMed Web of Science ®Google Scholar
• Ris-Stalpers C., Kuiper G.G., Faber P.W., Schweikert H.U., van Rooij H.C., Zegers N.D., Hodgins M.B., Degenhart H.J., Trapman J., Brinkmann A.O. Aberrant splicing of androgen receptor mRNA results in synthesis of a nonfunctional receptor protein in a patient with androgen insensitivity. Proc. Natl Acad. Sci. U.S.A. 1990; 87(20)7866–7870
   PubMed Web of Science ®Google Scholar
• Tilley W.D., Wilson C.M., Marcelli M., McPhaul M.J. Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res. 1990; 50(17)5382–5386
   PubMed Web of Science ®Google Scholar
• Simental J.A., Sar M., Lane M.V., French F.S., Wilson E.M. Transcriptional activation and nuclear targeting signals of the human androgen receptor. J. Biol. Chem. 1991; 266(1)510–518
   PubMed Web of Science ®Google Scholar
• Grino P.B., Isidro-Gutierrez R.F., Grinffin J.E., Wilson J.D. Androgen resistance associated with a qualitative abnormality of the androgen receptor and responsive to high dose androgen therapy. J. Clin. Endocrinol. Metab. 1989; 68(3)578–584
   PubMed Web of Science ®Google Scholar
• Tyagi R.K., Lavrovsky Y., Ahn S.C., Song C.S., Chatterjee B., Roy A.K. Dynamics of intracellular movement and nucleocytoplasmic recycling of the ligand-activated androgen receptor in living cells. Mol. Endocrinol. 2000; 14(8)1162–1174
   PubMed Web of Science ®Google Scholar
• Brinkmann A.O., Blok L.J., de Ruiter P.E., Doesburg P., Steketee K., Berrevoets C.A., Trapman J. Mechanisms of androgen receptor activation and function. J. Steroid. Biochem. Mol. Biol. 1999; 69(1–6)307–313
   PubMed Web of Science ®Google Scholar
• Quigley C.A., De Bellis A., Marschke K.B., el-Awady M.K., Wilson E.M., French F.S. Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr. Rev. 1995; 16(3)271–321
   PubMed Web of Science ®Google Scholar
• Jenster G. Coactivators and corepressors as mediators of nuclear receptor function: an update. Mol. Cell. Endocrinol. 1998; 143(1–2)1–7
   PubMed Web of Science ®Google Scholar
• Culig Z., Hobisch A., Hittmair A., Cronauer M.V., Radmayr C., Zhang J., Bartsch G., Klocker H. Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostatic carcinoma cells. Prostate 1997; 32(2)106–114
   PubMed Web of Science ®Google Scholar
• Culig Z., Hobisch A., Cronauer M.V., Radmayr C., Trapman J., Hittmair A., Bartsch G., Klocker H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 1994; 54(20)5474–5478
   PubMed Web of Science ®Google Scholar
• Hobisch A., Eder I.E., Putz T., Horninger W., Bartsch G., Klocker H., Culig Z. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res. 1998; 58(20)4640–4645
   PubMed Web of Science ®Google Scholar
• Gregory C.W., Johnson R.T., Jr., Mohler J.L., French F.S., Wilson E.M. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res. 2001; 61(7)2892–2898
   PubMed Web of Science ®Google Scholar
• Peterziel H., Mink S., Schonert A., Becker M., Klocker H., Cato A.C. Rapid signalling by androgen receptor in prostate cancer cells. Oncogene 1999; 18(46)6322–6329
   PubMed Web of Science ®Google Scholar
• Nagy L., Kao H.Y., Chakravarti D., Lin R.J., Hassig C.A., Ayer D.E., Schreiber S.L., Evans R.M. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 1997; 89(3)373–380
   PubMed Web of Science ®Google Scholar
• Heinzel T., Lavinsky R.M., Mullen T.M., Soderstrom M., Laherty C.D., Torchia J., Yang W.M., Brard G., Ngo S.D., Davie J.R., Seto E., Eisenman R.N., Rose D.W., Glass C.K., Rosenfeld M.G. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature 1997; 387(6628)43–48
   PubMed Web of Science ®Google Scholar
• Alland L., Muhle R., Hou H., Jr., Potes J., Chin L., Schreiber-Agus N., DePinho R.A. Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature 1997; 387(6628)49–55
   PubMed Web of Science ®Google Scholar
• Smith C.L., Nawaz Z., O'Malley B.W. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol. Endocrinol. 1997; 11(6)657–666
   PubMed Web of Science ®Google Scholar
• Jackson T.A., Richer J.K., Bain D.L., Takimoto G.S., Tung L., Horwitz K.B. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol. Endocrinol. 1997; 11(6)693–705
   PubMed Web of Science ®Google Scholar
• Zhang J., Guenther M.G., Carthew R.W., Lazar M.A. Proteasomal regulation of nuclear receptor corepressor-mediated repression. Genes Dev. 1998; 12(12)1775–1780
   PubMed Web of Science ®Google Scholar
• Wang L.G., Liu X.M., Kreis W., Budman D.R. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity. Biochem. Biophys. Res. Commun. 1999; 259(1)21–28
   PubMed Web of Science ®Google Scholar
• Blok L.J., de Ruiter P.E., Brinkmann A.O. Androgen receptor phosphorylation. Endocr. Res. 1996; 22(3)197–219
   PubMed Web of Science ®Google Scholar
• Kuiper G.G., de Ruiter P.E., Trapman J., Boersma W.J., Grootegoed J.A., Brinkmann A.O. Localization and hormonal stimulation of phosphorylation sites in the LNCaP-cell androgen receptor. Biochem. J. 1993; 291(Pt 1)95–101
   PubMedGoogle Scholar
• Wang L.G., Liu X.M., Kreis W., Budman D.R. Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor. Biochem. Pharmacol. 1998; 55(9)1427–1433
   PubMed Web of Science ®Google Scholar
• Nazareth L.V., Weigel N.L. Activation of the human androgen receptor through a protein kinase A signaling pathway. J. Biol. Chem. 1996; 271(33)19900–19907
   PubMed Web of Science ®Google Scholar
• Blok L.J., de Ruiter P.E., Brinkmann A.O. Forskolin-induced dephosphorylation of the androgen receptor impairs ligand binding. Biochemistry 1998; 37(11)3850–3857
   PubMed Web of Science ®Google Scholar
• Birrell S.N., Hall R.E., Tilley W.D. Role of the androgen receptor in human breast cancer. J. Mammary Gland Biol. Neoplasia 1998; 3(1)95–103
   PubMed Web of Science ®Google Scholar
• Spurdle A.B., Webb P.M., Chen X., Martin N.G., Giles G.G., Hopper J.L., Chenevix-Trench G. Androgen receptor exon 1 CAG repeat length and risk of ovarian cancer. Int. J. Cancer 2000; 87(5)637–643
   PubMed Web of Science ®Google Scholar
• McPhaul M.J., Marcelli M., Zoppi S., Griffin J.E., Wilson J.D. Genetic basis of endocrine disease. 4. The spectrum of mutations in the androgen receptor gene that causes androgen resistance. J. Clin. Endocrinol. Metab. 1993; 76(1)17–23
   PubMed Web of Science ®Google Scholar
• Pinsky L., Trifiro M., Kaufman M., Beitel L.K., Mhatre A., Kazemi-Esfarjani P., Sabbaghian N., Lumbroso R., Alvarado C., Vasiliou M., et al. Androgen resistance due to mutation of the androgen receptor. Clin. Invest. Med. 1992; 15(5)456–472
   PubMed Web of Science ®Google Scholar
• Trapman J., Brinkmann A.O. The androgen receptor in prostate cancer. Pathol. Res. Pract. 1996; 192(7)752–760
   PubMed Web of Science ®Google Scholar
• Lobaccaro J.M., Lumbroso S., Belon C., Galtier-Dereure F., Bringer J., Lesimple T., Namer M., Cutuli B.F., Pujol H., Sultan C. Androgen receptor gene mutation in male breast cancer. Hum. Mol. Genet. 1993; 2(11)1799–1802
   PubMed Web of Science ®Google Scholar
• Wooster R., Mangion J., Eeles R., Smith S., Dowsett M., Averill D., Barrett-Lee P., Easton D.F., Ponder B.A., Stratton M.R. A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome. Nat. Genet. 1992; 2(2)132–134
   PubMed Web of Science ®Google Scholar
• Hiort O., Naber S.P., Lehners A., Muletta-Feurer S., Sinnecker G.H., Zollner A., Komminoth P. The role of androgen receptor gene mutations in male breast carcinoma. J. Clin. Endocrinol. Metab. 1996; 81(9)3404–3407
   PubMed Web of Science ®Google Scholar
• Patterson M.N., Hughes I.A., Gottlieb B., Pinsky L. The androgen receptor gene mutations database. Nucleic Acids Res. 1994; 22(17)3560–3562
   PubMed Web of Science ®Google Scholar
• Gottlieb B., Beitel L.K., Trifiro M.A. Variable expressivity and mutation databases: the androgen receptor gene mutations database. Hum. Mutat. 2001; 17(5)382–388
   PubMed Web of Science ®Google Scholar
• Warner C.L., Griffin J.E., Wilson J.D., Jacobs L.D., Murray K.R., Fischbeck K.H., Dickoff D., Griggs R.C. X-linked spinomuscular atrophy: a kindred with associated abnormal androgen receptor binding. Neurology 1992; 42(11)2181–2184
   PubMed Web of Science ®Google Scholar
• Brinkmann A.O., Jenster G., Ris-Stalpers C., van der Korput J.A., Bruggenwirth H.T., Boehmer A.L., Trapman J. Androgen receptor mutations. J. Steroid Biochem. Mol. Biol. 1995; 53(1–6)443–448
   PubMed Web of Science ®Google Scholar
• Kennedy W.R., Alter M., Sung J.H. Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology 1968; 18(7)671–680
   PubMed Web of Science ®Google Scholar
• Robitaille Y., Lopes-Cendes I., Becher M., Rouleau G., Clark A.W. The neuropathology of CAG repeat diseases: review and update of genetic and molecular features. Brain Pathol. 1997; 7(3)901–926
   PubMed Web of Science ®Google Scholar
• Nance M.A. Clinical aspects of CAG repeat diseases. Brain Pathol. 1997; 7(3)881–900
   PubMed Web of Science ®Google Scholar
• Doyu M., Sobue G., Kimata K., Yamamoto K., Mitsuma T. Androgen receptor mRNA with increased size of tandem CAG repeat is widely expressed in the neural and nonneural tissues of X-linked recessive bulbospinal neuronopathy. J. Neurol. Sci. 1994; 127(1)43–47
   PubMed Web of Science ®Google Scholar
• Jepson A.S., Fentiman I.S. Male breast cancer. Int. J. Clin. Pract. 1998; 52(8)571–576
   PubMed Web of Science ®Google Scholar
• Thomas D.B., Jimenez L.M., McTiernan A., Rosenblatt K., Stalsberg H., Stemhagen A., Thompson W.D., Curnen M.G., Satariano W., Austin D.F., et al. Breast cancer in men: risk factors with hormonal implications. Am. J. Epidemiol. 1992; 135(7)734–748
   PubMed Web of Science ®Google Scholar
• Poujol N., Lobaccaro J.M., Chiche L., Lumbroso S., Sultan C. Functional and structural analysis of R607Q and R608K androgen receptor substitutions associated with male breast cancer. Mol. Cell Endocrinol. 1997; 130(1–2)43–51
   PubMed Web of Science ®Google Scholar
• Young I.E., Kurian K.M., Mackenzie M.A., Kunkler I.H., Cohen B.B., Hooper M.L., Wyllie A.H., Steel C.M. The CAG repeat within the androgen receptor gene in male breast cancer patients. J. Med. Genet. 2000; 37(2)139–140
   PubMed Web of Science ®Google Scholar
• Park J.J., Irvine R.A., Buchanan G., Koh S.S., Park J.M., Tilley W.D., Stallcup M.R., Press M.F., Coetzee G.A. Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor. Cancer Res. 2000; 60(21)5946–5949
   PubMed Web of Science ®Google Scholar
• Sandford N.L., Searle J.W., Kerr J.F. Successive wave of apoptosis in the rat prostate after repeated withdrawal of testosterone stimulation. Pathology 1984; 16(4)406–410
   PubMed Web of Science ®Google Scholar
• Kyprianou N., Isaacs J.T. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 1988; 122: 552–562
   PubMed Web of Science ®Google Scholar
• English H.F., Kyprianou N., Isaacs J.T. Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate 1989; 15(3)233–250
   PubMed Web of Science ®Google Scholar
• Wilding G. The importance of steroid hormones in prostate cancer. Cancer Surv. 1992; 14: 113–130
   PubMedGoogle Scholar
• Hakimi J.M., Rondinelli R.H., Schoenberg M.P., Barrack E.R. Androgen-receptor gene structure and function in prostate cancer. World J. Urol. 1996; 14(5)329–337
   PubMed Web of Science ®Google Scholar
• Shaneyfelt T., Husein R., Bubley G., Mantzoros C.S. Hormonal predictors of prostate cancer: a meta-analysis. J. Clin. Oncol. 2000; 18(4)847–853
   PubMed Web of Science ®Google Scholar
• Stewart R.J., Panigrahy D., Flynn E., Folkman J. Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J. Urol. 2001; 165(2)688–693
   PubMed Web of Science ®Google Scholar
• Rocchi P., Boudouresque F., Zamora A.J., Muracciole X., Lechevallier E., Martin P.M., Quafik L. Expression of adrenomedullin and peptide amidation activity in human prostate cancer and in human prostate cancer cell lines. Cancer Res. 2001; 61(3)1196–1206
   PubMed Web of Science ®Google Scholar
• Tso C.L., McBride W.H., Sun J., Patel B., Tsui K.H., Paik S.H., Gitlitz B., Caliliw R., van Ophoven A., Wu L., deKernion J., Belldegrun A. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. Cancer J. 2000; 6(4)220–233
   PubMed Web of Science ®Google Scholar
• van der Kwast T.H., Schalken J., Ruizeveld de Winter J.A., van Vroonhoven C.C., Mulder E., Boersma W., Trapman J. Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int. J. Cancer 1991; 48(2)189–193
   PubMed Web of Science ®Google Scholar
• Ruizeveld de Winter J.A., Janssen P.J., Sleddens H.M., Verleum-Mooijman M.C., Trapman J., Brinkmann A.O., Santerse A.B., Schroder F.H., van der Kwast T.H. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am. J. Pathol. 1994; 144(4)735–746
   PubMed Web of Science ®Google Scholar
• Brinkmann A.O., Trapman J. Prostate cancer schemes for androgen escape [news; comment]. Nat. Med. 2000; 6(6)628–629
   PubMed Web of Science ®Google Scholar
• Mononen N., Syrjakoski K., Matikainen M., Tammela T.L., Schleutker J., Kallioniemi O.P., Trapman J., Koivisto P.A. Two percent of Finnish prostate cancer patients have a germ-line mutation in the hormone-binding domain of the androgen receptor gene [In Process Citation]. Cancer Res. 2000; 60(22)6479–6481
   PubMed Web of Science ®Google Scholar
• Culig Z., Hobisch A., Hittmair A., Cronauer M.V., Radmayr C., Bartsch G., Klocker H. Androgen receptor gene mutations in prostate cancer. Implications for disease progression and therapy. Drugs Aging 1997; 10(1)50–58
   PubMed Web of Science ®Google Scholar
• Newmark J.R., Hardy D.O., Tonb D.C., Carter B.S., Espstein J.I., Isaacs W.B., Brown T.R., Barrack E.R. Androgen receptor gene mutations in human prostate cancer. Proc. Natl Acad. Sci. U.S.A. 1992; 89(14)6319–6323
   PubMed Web of Science ®Google Scholar
• Horoszewicz J.S., Leong S.S., Kawinski E., Karr J.P., Rosenthal H., Chu T.M., Mirand E.A., Murphy G.P. LNCaP model of human prostatic carcinoma. Cancer Res. 1983; 43(4)1809–1818
   PubMed Web of Science ®Google Scholar
• Wilding G., Chen M., Gelmann E.P. Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 1989; 14(2)103–115
   PubMed Web of Science ®Google Scholar
• Veldscholte J., Berrevoets C.A., Brinkmann A.O., Grootegoed J.A., Mudler E. Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry 1992; 31(8)2393–2399
   PubMed Web of Science ®Google Scholar
• Grigoryev D.N., Long B.J., Njar V.C., Brodie A.H. Pregnenolone stimulates LNCaP prostate cancer cell growth via the mutated androgen receptor. J. Steroid Biochem. Mol. Biol. 2000; 75(1)1–10
   PubMed Web of Science ®Google Scholar
• Veldscholte J., Ris-Stalpers C., Kuiper G.G., Jenster G., Berrevoets C., Claassen E., van Rooij H.C., Trapman J., Brinkmann A.O., Mulder E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun. 1990; 173(2)534–540
   PubMed Web of Science ®Google Scholar
• Culig Z., Klocker H., Eberle J., Kaspar F., Hobisch A., Cronauer M.V., Bartsch G. DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction. Prostate 1993; 22(1)11–22
   PubMed Web of Science ®Google Scholar
• Wen Y., Hu M.C., Makino K., Spohn B., Bartholomeusz G., Yan D.H., Hung M.C. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res. 2000; 60(24)6841–6845
   PubMed Web of Science ®Google Scholar
• Signoretti S., Montironi R., Manola J., Altimari A., Tam C., Bubley G., Balk S., Thomas G., Kaplan I., Hlatky L., Hahnfeldt P., Kantoff P., Loda M. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J. Natl Cancer Inst. 2000; 92(23)1918–1925
   PubMed Web of Science ®Google Scholar
• Junicho A., Matsuda T., Yamamoto T., Kishi H., Korkmaz K., Saatcioglu F., Fuse H., Muraguchi A. Protein inhibitor of activated STAT3 regulates androgen receptor signaling in prostate carcinoma cells [In Process Citation]. Biochem. Biophys. Res. Commun. 2000; 278(1)9–13
   PubMed Web of Science ®Google Scholar
• Reid P., Kantoff P., Oh W. Antiandrogens in prostate cancer. Investig. New Drugs 1999; 17(3)271–284
   PubMed Web of Science ®Google Scholar
• Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000; 355(9214)1491–1498
   PubMed Web of Science ®Google Scholar
• Wang J., Halford S., Rigg A., Roylance R., Lyrch M., Waxman J. Adjuvant mitozantrone chemotherapy in advanced prostate cancer. BJU Int. 2000; 86(6)675–680
   PubMed Web of Science ®Google Scholar
• Paul R., Breul J. Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance. Drug Saf. 2000; 23(5)381–390
   PubMed Web of Science ®Google Scholar
• Grossfeld G.D., Small E.J., Carroll P.R. Intermittent androgen deprivation for clinically localized prostate cancer: initial experience. Urology 1998; 51(1)137–144
   PubMed Web of Science ®Google Scholar
• Goldenberg S.L., Gleave M.E., Taylor D., Bruchovsky N. Clinical experience with intermittent androgen suppression in prostate cancer: minimum of 3 years' follow-up. Mol. Urol. 1999; 3(3)287–292
   PubMedGoogle Scholar
• Crook J.M., Szumacher E., Malone S., Huan S., Segal R. Intermittent androgen suppression in the management of prostate cancer. Urology 1999; 53(3)530–534
   PubMed Web of Science ®Google Scholar
• Leibowitz R.L., Tucker S.J. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients. Oncologist 2001; 6(2)177–182
   PubMed Web of Science ®Google Scholar
• Small E.J., Carroll P.R. Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 1994; 43(3)408–410
   PubMed Web of Science ®Google Scholar
• Kelly W.K. Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer. Eur. Urol. 1998; 34(Suppl 3)18–23
   PubMedGoogle Scholar
• Wolfe J.A. Palaeobotanical evidence for a marked temperature increase following the cretaceous/tertiary boundary. Nature 1990; 343: 153–156
   Web of Science ®Google Scholar
• Wirth M.P., Froschermaier S.E. The antiandrogen withdrawal syndrome. Urol. Res. 1997; 25(Suppl 2)S67–S71
   Google Scholar
• Fenton M.A., Shuster T.D., Fertig A.M., Taplin M.E., Kolvenbag G., Bubley G.J., Balk S.P. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin. Cancer Res. 1997; 3(8)1383–1388
   PubMed Web of Science ®Google Scholar
• Wolff J.M., Tunn U.W. Intermittent androgen blockade in prostate cancer: rationale and clinical experience. Eur. Urol. 2000; 38(4)365–371
   PubMed Web of Science ®Google Scholar
• Bruchovsky N., Klotz L.H., Sadar M., Crook J.M., Hoffart D., Godwin L., Warkentin M., Gleave M.E., Goldenberg S.L. Intermittent androgen suppression for prostate cancer: Canadian prospective trial and related observations. Mol. Urol. 2000; 4(3)191–200
   PubMedGoogle Scholar
• Kuil C.W., Berrevoets C.A., Mulder E. Ligand-induced conformational alterations of the androgen receptor analyzed by limited trypsinization. Studies on the mechanism of antiandrogen action. J. Biol. Chem. 1995; 270(46)27569–27576
   PubMed Web of Science ®Google Scholar
• Brinkmann A.O., Lindh L.M., Breedveld D.I., Mulder E., Van Der Molen H.J. Cyproterone acetate prevents translocation of the androgen receptor in the rat prostate. Mol. Cell Endocrinol. 1983; 32(2–3)117–129
   PubMed Web of Science ®Google Scholar
• Segnitz B., Gehring U. Mechanism of action of a steroidal antiglucocorticoid in lymphoid cells. J. Biol. Chem. 1990; 265(5)2789–2796
   PubMed Web of Science ®Google Scholar
• Fawell S.E., Lees J.A., White R., Parker M.G. Characterization and colocalization of steroid binding and dimerization activities in the mouse estrogen receptor. Cell 1990; 60(6)953–962
   PubMed Web of Science ®Google Scholar
• Klein-Hitpass L., Cato A.C., Henderson D., Ryffel G.U. Two types of antiprogestins identified by their differential action in transcriptionally active extracts from T47D cells. Nucleic Acids Res. 1991; 19(6)1227–1234
   PubMed Web of Science ®Google Scholar
• Kuil C.W., Brinkmann A.O. Androgens, antiandrogens and androgen receptor abnormalities. Eur. Urol. 1996; 29(Suppl 2)78–82
   PubMedGoogle Scholar
• Reese J.C., Katzenellenbogen B.S. Differential DNA-binding abilities of estrogen receptor occupied with two classes of antiestrogens: studies using human estrogen receptor overexpressed in mammalian cells. Nucleic Acids Res. 1991; 19(23)6595–6602
   PubMed Web of Science ®Google Scholar
• Miyamoto H., Yeh S., Wilding G., Chang C. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proc. Natl Acad. Sci. U. S. A. 1998; 95(13)7379–7384
   PubMed Web of Science ®Google Scholar
• Neumann F., Topert M. Pharmacology of antiandrogens. J. Steroid Biochem. 1986; 25(5B)885–895
   PubMedGoogle Scholar
• Raynaud J.P., Ojasoo T. The design and use of sex-steroid antagonists. J. Steroid Biochem. 1986; 25(5B)811–833
   PubMedGoogle Scholar
• Kemppainen J.A., Lane M.V., Sar M., Wilson E.M. Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones. J. Biol. Chem. 1992; 267(2)968–974
   PubMed Web of Science ®Google Scholar
• Mahler C., Verhelst J., Denis L. Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer. Clin. Pharmacokinet. 1998; 34(5)405–417
   PubMed Web of Science ®Google Scholar
• Goldenberg S.L., Bruchovsky N. Use of cyproterone acetate in prostate cancer. Urol. Clin. N. Am. 1991; 18(1)111–122
   PubMed Web of Science ®Google Scholar
• Frith R.G., Phillipou G. 15-Hydroxycyproterone acetate and cyproterone acetate levels in plasma and urine. J. Chrom. 1985; 338(1)179–186
   PubMed Web of Science ®Google Scholar
• Blake J.C., Sawyerr A.M., Dooley J.S., Scheuer P.J., McIntyre N. Severe hepatitis caused by cyproterone acetate. Gut 1990; 31(5)556–557
   PubMed Web of Science ®Google Scholar
• Dawson N.A., Conaway M., Halabi S., Winer E.P., Small E.J., Lake D., Vogelzang N.J. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181. Cancer 2000; 88(4)825–834
   PubMed Web of Science ®Google Scholar
• Crombie C., Raghavan D., Page J., Woods R., Dalley D., Devine R., Rosen M. Phase II study of megestrol acetate for metastatic carcinoma of the prostate. Br. J. Urol. 1987; 59(5)443–446
   PubMedGoogle Scholar
• Wong C., Kelce W.R., Sar M., Wilson E.M. Androgen receptor antagonist versus agonist activities of the fungicide vinclozolin relative to hydroxyflutamide. J. Biol. Chem. 1995; 270(34)19998–20003
   PubMed Web of Science ®Google Scholar
• Dankoff J.S. Near fatal liver dysfunction secondary to administration of flutamide for prostate cancer. J. Urol. 1992; 148(6)1914
   PubMed Web of Science ®Google Scholar
• Kuhn J.M., Billebaud T., Navratil H., Moulonguet A., Fiet J., Grise P., Louis J.F., Costa P., Husson J.M., Dahan R., et al. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N. Engl. J. Med. 1989; 321(7)413–418
   PubMed Web of Science ®Google Scholar
• Decensi A., Guarneri D., Paoletti M.C., Lalanne J.M., Merlo F., Boccardo F. Phase II study of the pure non-steroidal antiandrogen nilutamide in prostatic cancer. Italian Prostatic Cancer Project (PONCAP). Eur. J. Cancer 1991; 27(9)1100–1104
   PubMed Web of Science ®Google Scholar
• Blackledge G.R., Cockshott I.D., Furr B.J. Casodex (bicalutamide): overview of a new antiandrogen developed for the treatment of prostate cancer. Eur. Urol. 1997; 31(Suppl 2)30–39
   PubMedGoogle Scholar
• Culig Z., Hoffmann J., Erdel M., Eder I.E., Hobisch A., Hittmair A., Bartsch G., Utermann G., Schneider M.R., Parczyk K., Klocker H. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br. J. Cancer 1999; 81(2)242–251
   PubMed Web of Science ®Google Scholar
• Laufer M., Sinibaldi V.J., Carducci M.A., Eisenberger M.A. Rapid disease progression after the administration of bicalutamide in patients with metastatic prostate state cancer. Urology 1999; 54(4)745
   PubMedGoogle Scholar
• Suzuki H., Sato N., Watabe Y., Masai M., Seino S., Shimazaki J. Androgen receptor gene mutations in human prostate cancer. J. Steroid Biochem. Mol. Biol. 1993; 46(6)759–765
   PubMed Web of Science ®Google Scholar
• Culig Z., Hobisch A., Cronauer M.V., Cato A.C., Hittmair A., Radmayr C., Eberle J., Bartsch G., Klocker H. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol. Endocrinol. 1993; 7(12)1541–1550
   PubMed Web of Science ®Google Scholar
• Peterziel H., Culig Z., Stober J., Hobisch A., Radmayr C., Bartsch G., Klocker H., Cato A.C. Mutant androgen receptors in prostatic tumors distinguish between amino-acid-sequence requirements for transactivation and ligand binding. Int. J. Cancer 1995; 63(4)544–550
   PubMed Web of Science ®Google Scholar
• Elo J.P., Kvist L., Leinonen K., Isomaa V., Henttu P., Lukkarinen O., Vihko P. Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol. J. Clin. Endocrinol. Metab. 1995; 80(12)3494–3500
   PubMed Web of Science ®Google Scholar
• Taplin M.E., Bubley G.J., Shuster T.D., Frantz M.E., Spooner A.E., Ogata G.K., Keer H.N., Balk S.P. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 1995; 332(21)1393–1398
   PubMed Web of Science ®Google Scholar
• Gaddipati J.P., McLeod D.G., Heidenberg H.B., Sesterhenn I.A., Finger M.J., Moul J.W., Srivastava S. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res. 1994; 54(11)2861–2864
   PubMed Web of Science ®Google Scholar
• Ris-Stalpers C., Verleun-Mooijman M.C., Trapman J., Brinkmann A.O. Threonine on amino acid position 868 in the human androgen receptor is essential for androgen binding specificity and functional activity. Biochem. Biophys. Res. Commun. 1993; 196(1)173–180
   PubMed Web of Science ®Google Scholar